Coya Therapeutics招募第100名参与者参加COYA 302的ALSTARS 2/3期试验

2026-09-15 20:03

Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027
Additional participants continue to roll over into the active extension arm of the trial
COYA 302 has received FDA Fast Track designation for the treatment of ALS

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。